Navigation Links
Myc inhibition is an effective therapeutic strategy against most aggressive brain tumors
Date:8/18/2014

Barcelona, 18 August 2014. Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies. The study led by Laura Soucek, Principal Investigator of VHIOs Mouse Models of Cancer Therapies Group, published today in Nature Communications, not only represents an important step forward in ultimately providing brain glioma patients with new therapeutic avenues, but also reveals new insights into the biology of Myc that could further impact on its therapeutic potential.

In a study published last year, the group succeded in eradicating lung tumors in transgenic mice by adopting the same strategy involving the expression of Omomyc, a Myc inhibitor designed by Soucek. They also confirmed that there were no side effects post-administration of repeated and long-term treatment. Importantly, there was no evidence of resistance to therapy -- one of the greatest challenges in the treatment of cancer. These results therefore confirmed Myc inhibition as a sound and effective therapeutic strategy for the development of novel cancer drugs.

Soucek and her group were to raise the bar yet higher. Firstly, the focus on gene expression-based therapy under experimental study progressed and re-programed on the development of an administrable Omomyc-based drug. Second, the group continued to show the efficacy of Myc inhibition across different tumors and, above and beyond transgenic models, they showed the same success in human tumors using a technique that transfers human cancer cells to immunodeficient mice. "Upon reporting initial results at preclinical level, our main concern was how do demonstrate these findings in human tumors," says Laura Soucek. "Firstly, we focused on how they could apply to other tissues and other more aggressive tumor types for wh
'/>"/>

Contact: Amanda Wren
awren@vhio.net
34-695-207-886
Vall dHebron Institute of Oncology
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Enzyme-inhibition could revolutionize molecular imaging
2. Inhibition of CDK4 might promote lymphoma development and progression
3. Inhibition of oral biofilm and cell-cell communication using natural-products derivatives
4. New STELARA data show inhibition of joint destruction in active psoriatic arthritis
5. Epoxide hydrolase inhibition and Thiazolidinediones: A therapy for cardiometabolic syndrome
6. Neurological Wellness Center's Novel Neuro-Inflammation Inhibition Procedure that Induces Rapid Recovery from Alzheimer's, Stroke and Brain Injury is Now Being Taught in a Newly Released Video
7. Novel test identifies patients most likely to benefit from ALK inhibition therapy
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
10. New Book on Stuttering Dispels Myths Offers New Insights for Effective Treatment
11. High-intensity exercise found safe and effective in long-term heart transplant recipients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Myc inhibition is an effective therapeutic strategy against most aggressive brain tumors
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... FL (PRWEB) December 17, 2014 No ... not been able to eradicate the head louse parasite—a ... hassle for parents. Each year between six and twelve ... Troopers, the Miami-based lice removal treatment company comes to ... non-toxic and environmentally friendly. With its track record of ...
(Date:12/17/2014)... As gas prices rose in recent years, so did ... In times of gas increases, more people start using ... researchers explained. They examined data gathered between 2002 ... of motorcycle registrations in the United States and the ... revealed a strong association between rising gas prices and ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Poor students get more ... a new study finds. But, the opposite is true ... having fruits and vegetables at school may give a healthy ... But, no matter what the family income level, students all ... the study found. The study was published recently in ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... drug manufacturers- Merck &Co. //The issue in contention is the ... no call to charge as much as 1.59 US dollars ... for the same. , Negotiations between Merck and ... declared the drug a ‘public interest’ one. This means that ...
... has confirmed that the malfunction of a gene causes ... issue of the journal Neuron. ,The researchers said ... for developing treatments for schizophrenia and depression, which have ... researchers. ,In their experiments, the researchers sought ...
... diseases has entered the phase of clinical experiments, claimed a ... on antigen or antibody test, the new technology is based ... to confirm epidemic diseases such as hepatitis or AIDS, said ... National Institutes of Health (NIH). ,Xiang was speaking ...
... liver transplant recipients without hepatitis C (HCV), survival has ... has not improved//, according to a study in the ... is the most common reason for liver transplantation in ... patients do not respond as well to liver transplantation. ...
... areas have had enough. Most Doctors are on the brink ... A survey conducted by the Australian Medical Association has found ... the staff shortage, outdated equipments and under trained colleagues from ... wards have closed down due to the shortage of doctors. ...
... young children in Australian are succumbing to infections. And that ... more parents// fall back on the day care centres. ... West Australian children found infectious diseases were the most common ... ,Researchers at the Telethon Institute for Child Health Research found ...
Cached Medicine News:Health News:Brazil Government In Contention With Merck Over Anti-AIDS Drug 2Health News:Malfunction of Gene Causes Schizophrenia, Depression 2Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram ... by 2016. The North America ... share while Europe claims approximately ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... , ... ... ... ...
... ... ... ... , ...
Cached Medicine Technology:Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 2Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 3Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 4Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 5Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 6Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 7Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 8Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 9Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 10Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 11Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 12Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 13Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 14Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 15Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 16Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 17Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 18Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 2Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 3Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 4Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 5
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... The HemoPoint H2 Hemoglobin Measurement ... determination of hemoglobin in arterial, venous, ... infants, and children in a professional ... number 3010-100 is indicated for use ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... DCL's ImmunoDip Test For Microalbuminuria. ... urine,sample. The patented housing will draw,the precise ... , Self-Timing: ,The ImmunoDip will run ... Easy to Read Colors: ,The resulting color ...
Medicine Products: